Q4 2025 revenue was 30615000, flat year-over-year, as Commercial Channel revenue increased 22% to 13302000 while OEM Channel revenue declined 12% to 17313000. Gross margin expanded to 63% and GAAP income from continuing operations was 1801000.

Anika Therapeutics reported a 10% decrease in first quarter revenue from continuing operations compared to the same period in 2024, totaling $26.2 million. The Commercial Channel saw an 18% increase, driven by Integrity and international OA Pain Management, while the OEM Channel decreased by 23% due to lower pricing. The company achieved key regulatory and clinical milestones for Hyalofast and Cingal, and operating expenses declined by 12%.

Anika's Q4 2024 revenue was $30.6 million, reflecting a 1% year-over-year increase. The Commercial Channel grew 25%, driven by the Integrity Implant System and International OA Pain Management, while the OEM Channel declined 8%. The company reported a net loss of $2.5 million and an adjusted net loss of $0.3 million.

Anika Therapeutics reported a 7% decrease in third-quarter revenue compared to the previous year, totaling $38.8 million. The decline was primarily due to challenges in the U.S. OA Pain Management sector, though this was partially offset by growth in international OA Pain Management and a 17% increase in the Regenerative Solutions business. Anika is restructuring to focus on its Commercial Channel and core HA technology.

Anika Therapeutics reported their Q2 2024 financial results, highlighting the full market release of the Integrity™ Implant System and a 17% growth in international OA Pain Management revenue during the first half of 2024. The company also announced a new $40 million share repurchase program and is optimizing spending to support growth.

Anika Therapeutics reported a 7% increase in revenue for Q1 2024, driven by strong performance in the OA Pain Management platform and cost discipline. The company is on track to achieve its 2024 revenue and adjusted EBITDA guidance.

Anika Therapeutics reported strong fourth quarter and full year results, with a record year in OA Pain Management. The company is implementing cost reduction initiatives expected to provide annualized savings of approximately $10 million. Anika anticipates adjusted EBITDA of $25 to $30 million in 2024.

Anika Therapeutics reported strong third quarter results with revenue growth exceeding expectations. Joint Preservation and Restoration was up 14% and OA Pain Management was up 2%. The company also raised its overall revenue outlook for fiscal year 2023 to between $164 million and $166 million.

Anika Therapeutics reported strong second-quarter results, with double-digit revenue growth driven by OA Pain Management. The company is making significant progress with its Hyalofast Phase III trial and advancing the development of Integrity. Anika updated its full-year revenue outlook to $159.5 million to $163 million.

Anika Therapeutics reported solid top line performance in Q1 2023, with double-digit growth in Joint Preservation and Restoration and solid growth in OA Pain Management. The company is on track for the full market release of RevoMotion Reverse Shoulder system in late 2023 and the launch of a regenerative rotator cuff patch system in 2024.

Anika Therapeutics reported strong operational and financial performance in Q4 2022, with revenue growth driven by its market-leading OA Pain Management business and investments in new products across regenerative, sports medicine, and joint solutions.

Anika Therapeutics reported solid financial performance in the third quarter, marked by a 2% revenue growth. The company saw positive results from the X-Twist Fixation System limited launch and successful Cingal Phase III clinical trial. They are on track to achieve FY2022 guidance.

Anika Therapeutics reported solid second quarter results, with continued momentum in their regenerative solutions portfolio. The company received FDA 510(k) clearance for their X-Twist Fixation System and is on track for a limited market release in the second half of the year.

Anika Therapeutics reported a strong start to 2022 with a 7% year-over-year revenue growth. The company is experiencing healthy demand for OA Pain Management products and growing demand for the Joint Preservation and Restoration portfolio. They are ramping up medical education activities and planning new product introductions.

Anika Therapeutics reported a 10% year-over-year revenue growth in the fourth quarter, ending the year with a 13% revenue increase for fiscal year 2021. The company faced COVID-related market challenges but saw strong growth in its Joint Preservation and Restoration business.

Anika Therapeutics reported a 25% year-over-year revenue growth for the third quarter of 2021. The company has revised its revenue growth outlook for 2021 to 9-11% due to COVID Delta headwinds.

Anika Therapeutics reported a strong second quarter with revenue growth of 24% year-over-year. The company is making significant progress in its business transformation and expects double digit revenue growth in 2021. They have also raised their full year revenue growth outlook to 11-14%.

Anika Therapeutics reported its first quarter 2021 financial results, showing a slight decrease in revenue compared to pre-COVID levels in the prior year. However, the company's Joint Preservation revenue saw a significant increase of 55%. The company is maintaining its expectations for revenue growth in 2021.

Anika Therapeutics reported a 10% year-over-year revenue increase for Q4 2020, contributing to a 14% revenue increase for the full year. The company successfully integrated Parcus Medical and Arthrosurface acquisitions, diversifying its portfolio and business.

Anika Therapeutics reported a 7% year-over-year revenue increase to $31.7 million in Q3 2020. The company repaid $25 million of its outstanding credit facility and continued to expand its joint preservation product portfolio.

Anika Therapeutics reported a 1% year-over-year increase in total revenue to $30.7 million for the second quarter of 2020. The company is integrating Parcus Medical and Arthrosurface and launching seven FDA-cleared products through Q3 2020.

Anika Therapeutics reported solid first-quarter results, with total revenue increasing by 43% year-over-year. The company completed the acquisitions of Parcus Medical and Arthrosurface and strengthened its executive leadership team. Due to the COVID-19 pandemic, Anika has withdrawn its full-year 2020 financial guidance but is well-positioned to manage through the challenges.

Anika Therapeutics reported a 10% year-over-year increase in total revenue for the fourth quarter of 2019. The company completed acquisitions of Parcus Medical and Arthrosurface and expects total revenue growth in the 40% to 44% range for the full year 2020.